David J Cohen1, Ruben L Osnabrugge2, Elizabeth A Magnuson2, Kaijun Wang2, Haiyan Li2, Khaja Chinnakondepalli2, Duane Pinto2, Mouin S Abdallah2, Katherine A Vilain2, Marie-Claude Morice2, Keith D Dawkins2, A Pieter Kappetein2, Friedrich W Mohr2, Patrick W Serruys2. 1. From Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City (D.J.C., R.L.O., E.A.M., K.W., H.L., K.C.); Erasmus University Medical Center, Rotterdam, The Netherlands (R.L.O., A.P.K., P.W.S.); Harvard School of Public Health, Boston, MA (D.P.); Institut Jacques Cartier, Massy, France (M.-C.M.); Boston Scientific, Natick, MA (K.D.D.); and Herzzentrum Universität Leipzig, Leipzig, Germany (F.W.M.). dcohen@saint-lukes.org. 2. From Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City (D.J.C., R.L.O., E.A.M., K.W., H.L., K.C.); Erasmus University Medical Center, Rotterdam, The Netherlands (R.L.O., A.P.K., P.W.S.); Harvard School of Public Health, Boston, MA (D.P.); Institut Jacques Cartier, Massy, France (M.-C.M.); Boston Scientific, Natick, MA (K.D.D.); and Herzzentrum Universität Leipzig, Leipzig, Germany (F.W.M.).
Abstract
BACKGROUND: The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial demonstrated that in patients with 3-vessel or left main coronary artery disease, coronary artery bypass graft surgery (CABG) was associated with a lower rate of cardiovascular death, myocardial infarction, stroke, or repeat revascularization compared with percutaneous coronary revascularization with drug-eluting stents (DES-PCI)). The long-term cost-effectiveness of these strategies is unknown. METHODS AND RESULTS:Between 2005 and 2007, 1800 patients with left main or3-vessel coronary artery disease were randomized to CABG (n=897) or DES-PCI (n=903). Costs were assessed from a US perspective, and health state utilities were evaluated with the EuroQOL questionnaire. A patient-level microsimulation model based on the 5-year in-trial data was used to extrapolate costs, life expectancy, and quality-adjusted life expectancy over a lifetime horizon. Although initial procedural costs were $3415 per patient lower with CABG, total hospitalization costs were $10 036 per patient higher. Over the next 5 years, follow-up costs were higher with DES-PCI as a result of more frequent hospitalizations, revascularization procedures, and higher medication costs. Over a lifetime horizon, CABG remained more costly than DES-PCI, but the incremental cost-effectiveness ratio was favorable ($16 537 per quality-adjusted life-year gained) and remained <$20 000 per quality-adjusted life-year in most bootstrap replicates. Results were consistent across a wide range of assumptions about the long-term effect of CABG versus DES-PCI on events and costs. In patients with left main disease or a SYNTAX score ≤22, however, DES-PCI was economically dominant compared with CABG, although these findings were less certain. CONCLUSIONS: For most patients with 3-vessel or left main coronary artery disease, CABG is a clinically and economically attractive revascularization strategy compared with DES-PCI. However, among patients with less complex disease, DES-PCI may be preferred on both clinical and economic grounds. CLINICAL TRIAL REGISTRATION URL: www.clinicaltrials.gov. Unique identifier: NCT00114972.
RCT Entities:
BACKGROUND: The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial demonstrated that in patients with 3-vessel or left main coronary artery disease, coronary artery bypass graft surgery (CABG) was associated with a lower rate of cardiovascular death, myocardial infarction, stroke, or repeat revascularization compared with percutaneous coronary revascularization with drug-eluting stents (DES-PCI)). The long-term cost-effectiveness of these strategies is unknown. METHODS AND RESULTS: Between 2005 and 2007, 1800 patients with left main or 3-vessel coronary artery disease were randomized to CABG (n=897) or DES-PCI (n=903). Costs were assessed from a US perspective, and health state utilities were evaluated with the EuroQOL questionnaire. A patient-level microsimulation model based on the 5-year in-trial data was used to extrapolate costs, life expectancy, and quality-adjusted life expectancy over a lifetime horizon. Although initial procedural costs were $3415 per patient lower with CABG, total hospitalization costs were $10 036 per patient higher. Over the next 5 years, follow-up costs were higher with DES-PCI as a result of more frequent hospitalizations, revascularization procedures, and higher medication costs. Over a lifetime horizon, CABG remained more costly than DES-PCI, but the incremental cost-effectiveness ratio was favorable ($16 537 per quality-adjusted life-year gained) and remained <$20 000 per quality-adjusted life-year in most bootstrap replicates. Results were consistent across a wide range of assumptions about the long-term effect of CABG versus DES-PCI on events and costs. In patients with left main disease or a SYNTAX score ≤22, however, DES-PCI was economically dominant compared with CABG, although these findings were less certain. CONCLUSIONS: For most patients with 3-vessel or left main coronary artery disease, CABG is a clinically and economically attractive revascularization strategy compared with DES-PCI. However, among patients with less complex disease, DES-PCI may be preferred on both clinical and economic grounds. CLINICAL TRIAL REGISTRATION URL: www.clinicaltrials.gov. Unique identifier: NCT00114972.
Authors: Pamela Samson; Aalok Patel; Cliff G Robinson; Daniel Morgensztern; Su-Hsin Chang; Graham A Colditz; Saiama Waqar; Traves D Crabtree; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Bryan F Meyers; Varun Puri Journal: Ann Thorac Surg Date: 2015-08-25 Impact factor: 4.330
Authors: Vinay Kini; Nidhi Mehta; Jeremy A Mazurek; Victor A Ferrari; Andrew J Epstein; Peter W Groeneveld; James N Kirkpatrick Journal: J Am Soc Echocardiogr Date: 2015-07-10 Impact factor: 5.251
Authors: Zugui Zhang; Paul Kolm; Maria V Grau-Sepulveda; Angelo Ponirakis; Sean M O'Brien; Lloyd W Klein; Richard E Shaw; Charles McKay; David M Shahian; Frederick L Grover; John E Mayer; Kirk N Garratt; Mark Hlatky; Fred H Edwards; William S Weintraub Journal: J Am Coll Cardiol Date: 2015-01-06 Impact factor: 24.094
Authors: Robert H Habib; Kamellia R Dimitrova; Sanaa A Badour; Maroun B Yammine; Abdul-Karim M El-Hage-Sleiman; Darryl M Hoffman; Charles M Geller; Thomas A Schwann; Robert F Tranbaugh Journal: J Am Coll Cardiol Date: 2015-09-29 Impact factor: 24.094
Authors: Andrew Y Chang; Daniel Kaiser; Aditya Ullal; Alexander C Perino; Paul A Heidenreich; Mintu P Turakhia Journal: Arrhythm Electrophysiol Rev Date: 2014-11-29
Authors: Pranav Kansara; Sandra Weiss; William S Weintraub; Matthew C Hann; James Tcheng; S Tanveer Rab; Lloyd W Klein Journal: JACC Cardiovasc Interv Date: 2015-11 Impact factor: 11.195